April 25, 2019 / 12:17 PM / a month ago

Gilead's NASH drug fails to meet late-stage study goal

April 25 (Reuters) - Gilead Sciences Inc said on Thursday its experimental drug to treat scarring of tissue due to nonalcoholic steatohepatitis (NASH) did not meet main goal of a late stage trial.

NASH is a fatty liver disease where fat accumulation and inflammation can lead to scarring, or fibrosis, that impairs liver function. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below